Creative Medical Technology Holdings Inc. Common Stock (CELZ)

FairStock Score: 39/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market is offering this at $0.82 as of 2026-10-13, a $5.4 million market cap. I look first for a durable business. Creative Medical is a commercial-stage biotech with CaverStem, FemCelz, and early programs, but in fiscal year 2025, the year ended 2025-12-31, revenue was only $6,000 and net loss was $6.0 million. In fiscal year 2024, the year ended 2024-12-31, revenue was $11,000 and net loss was $5.5 million. In fiscal year 2023, the year ended 2023-12-31, revenue was $9,000 and net loss was $5.3 million. That is not a business with pricing power or a moat; it is a research effort with a commercial label. The quarterly filings show continuing losses: in fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $1.5 million and diluted EPS was $-0.41; in fiscal Q1 2026, the quarter ended 2026-03-31, net loss was $1.4 million and diluted EPS was $-0.38. Financial health is poor: trailing free cash flow is -$6.0 million, a -111.5% FCF yield, FairStock's Altman Z-score is -5.95, and its Piotroski F-score is 3/9. The only balance-sheet comfort is D/E of 0.00. Valuation: at the $0.82 close on 2026-10-13, FairStock's P/B is 0.62, below stated book value, but P/E is -0.40. The FairStock score is 39/100. The computed Lynch category is none, because it lost money in each of the last four years. With no profits and severe cash burn, book value is not a margin of safety unless the pipeline proves commercial. Growth trajectory? Revenue is negligible and losses persist. I would need evidence of sales before calling this cheap. It looks speculative, not an investment.

In plain English: Creative Medical Technology Holdings is a tiny biotech with treatments for sexual health and early cell-therapy programs. The business looks weak: it has almost no revenue and loses millions each year. The price is below stated book value, but because the company keeps losing money, it does not look clearly cheap, fair, or expensive in a normal business sense.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer